Boston's resTORbio Sets Terms for $85M IPO Post author:Sam Post published:January 16, 2018 Post category:BioPharma resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace You Might Also Like TiGenix Begins Recruiting for New U.S. HQ in Massachusetts June 28, 2017 Genetic Tech Exploring Strategic Alternatives August 24, 2017 12 Clinical Successes of 2017 December 17, 2017
